Propensity-adjusted Association of Methotrexate with Overall Survival in Rheumatoid Arthritis

Overview

Journal Arthritis Rheum

Specialty Rheumatology

Date 2012 Oct 10

PMID 23044791

Citations 45

Authors

Mary Chester M Wasko

Abhijit Dasgupta

Helen Hubert

James F Fries

Michael M Ward

Affiliations

Soon will be listed here.

Abstract

Objective: While medications used to treat rheumatoid arthritis (RA) may affect survival in RA, few studies take into account the propensity for medication use, which may reflect selection bias in treatment allocation in survival models. We undertook this study to examine the relationship between methotrexate (MTX) use and mortality in RA, after controlling for individual propensity scores for MTX use.

Methods: We studied 5,626 RA patients prospectively for 25 years to determine the risk of death associated with MTX use, modeled in time-varying Cox regression models. We used the random forest method to generate individual propensity scores for MTX use at study entry and during followup in a time-varying manner; these scores were included in the multivariate model. We also investigated whether selective discontinuation of MTX immediately prior to death altered the risk of mortality, and we examined the association of duration of MTX use with survival.

Results: During followup, 666 patients (12%) died. MTX use was associated with reduced risk of death (adjusted hazard ratio 0.30 [95% confidence interval 0.09-1.03]). Selective MTX cessation immediately before death did not account for the protective association of MTX use with mortality. Only MTX use for >1 year was associated with lower risks of mortality, but associations were not stronger with longer durations of use.

Conclusion: MTX use was associated with a 70% reduction in mortality in RA.

Citing Articles

Associations of gender with sexual functioning, loneliness, depression, fatigue and physical function amongst patients suffering from rheumatoid arthritis with a particular focus on methotrexate usage.

Bay L, Nielsen D, Flurey C, Giraldi A, Moller S, Graugaard C Rheumatol Int. 2024; 44(5):919-931.

PMID: 38483561 PMC: 10980642. DOI: 10.1007/s00296-024-05555-y.

Relationship between frailty and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients.

Sobue Y, Suzuki M, Ohashi Y, Koshima H, Okui N, Funahashi K Clin Rheumatol. 2023; 42(8):2069-2077.

PMID: 37211570 DOI: 10.1007/s10067-023-06639-z.

The Hypoxia-Adenosine Link during Myocardial Ischemia-Reperfusion Injury.

Ruan W, Ma X, Bang I, Liang Y, Muehlschlegel J, Tsai K Biomedicines. 2022; 10(8).

PMID: 36009485 PMC: 9405579. DOI: 10.3390/biomedicines10081939.

Development of a Risk Nomogram Model for Identifying Interstitial Lung Disease in Patients With Rheumatoid Arthritis.

Xue J, Hu W, Wu S, Wang J, Chi S, Liu X Front Immunol. 2022; 13:823669.

PMID: 35784288 PMC: 9245420. DOI: 10.3389/fimmu.2022.823669.

Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis.

Rojas-Serrano J, Mejia M, Rivera-Matias P, Herrera-Bringas D, Perez-Roman D, Perez-Dorame R Clin Rheumatol. 2022; 41(6):1741-1747.

PMID: 35112192 DOI: 10.1007/s10067-021-06040-8.

References

Westlake S, Colebatch A, Baird J, Kiely P, Quinn M, Choy E . The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2009; 49(2):295-307. DOI: 10.1093/rheumatology/kep366. View

Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

Kurth T, Walker A, Glynn R, Chan K, Gaziano J, Berger K . Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2005; 163(3):262-70. DOI: 10.1093/aje/kwj047. View

Hernan M, Hernandez-Diaz S, Robins J . A structural approach to selection bias. Epidemiology. 2004; 15(5):615-25. DOI: 10.1097/01.ede.0000135174.63482.43. View

Naranjo A, Sokka T, Descalzo M, Calvo-Alen J, Horslev-Petersen K, Luukkainen R . Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008; 10(2):R30. PMC: 2453774. DOI: 10.1186/ar2383. View

van Halm V, Nurmohamed M, Twisk J, Dijkmans B, Voskuyl A . Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006; 8(5):R151. PMC: 1779436. DOI: 10.1186/ar2045. View

Wolfe F, Mitchell D, Sibley J, Fries J, Bloch D, Williams C . The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37(4):481-94. DOI: 10.1002/art.1780370408. View

Gonzalez A, Kremers H, Crowson C, Nicola P, Davis 3rd J, Therneau T . The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007; 56(11):3583-7. DOI: 10.1002/art.22979. View

Ward M . Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs?. Arthritis Rheum. 2001; 44(6):1467-9. DOI: 10.1002/1529-0131(200106)44:6<1467::AID-ART243>3.0.CO;2-6. View

10.

Coomes E, Chan E, Reiss A . Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol. 2011; 2011:503028. PMC: 3070167. DOI: 10.1155/2011/503028. View

11.

Bernatsky S, Hudson M, Suissa S . Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005; 44(5):677-80. DOI: 10.1093/rheumatology/keh610. View

12.

Choi H, Hernan M, Seeger J, Robins J, Wolfe F . Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002; 359(9313):1173-7. DOI: 10.1016/S0140-6736(02)08213-2. View

13.

Austin P, Grootendorst P, Normand S, Anderson G . Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Stat Med. 2006; 26(4):754-68. DOI: 10.1002/sim.2618. View

14.

Solomon D, Avorn J, Katz J, Weinblatt M, Setoguchi S, Levin R . Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54(12):3790-8. DOI: 10.1002/art.22255. View

15.

Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C . Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther. 2010; 28(5):e53-64. DOI: 10.1111/j.1755-5922.2009.00119.x. View

16.

Gabriel S, Michaud K . Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009; 11(3):229. PMC: 2714099. DOI: 10.1186/ar2669. View

17.

Krause D, Schleusser B, Herborn G, Rau R . Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000; 43(1):14-21. DOI: 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7. View

18.

Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A . Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol. 2006; 33(9):1740-6. View

19.

Ridker P . Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009; 7 Suppl 1:332-9. DOI: 10.1111/j.1538-7836.2009.03404.x. View

20.

Fries J, Spitz P, Young D . The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982; 9(5):789-93. View